Beata Franczyk

List of Publications by Citations

Source: https://exaly.com/author-pdf/9125472/beata-franczyk-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

48 654 14 23 g-index

59 1,016 4.6 4.58 ext. papers ext. citations avg, IF L-index

| # | Paper | IF | Citations |
|----|--|-----|-----------|
| 48 | Novel Biomarkers in the Diagnosis of Chronic Kidney Disease and the Prediction of Its Outcome. <i>International Journal of Molecular Sciences</i> , 2017 , 18, | 6.3 | 112 |
| 47 | The Effect of Diet on the Survival of Patients with Chronic Kidney Disease. <i>Nutrients</i> , 2017 , 9, | 6.7 | 43 |
| 46 | Vegetarian Diet in Chronic Kidney Disease-A Friend or Foe. <i>Nutrients</i> , 2017 , 9, | 6.7 | 42 |
| 45 | Molecular mechanisms of statin intolerance. <i>Archives of Medical Science</i> , 2016 , 12, 645-58 | 2.9 | 40 |
| 44 | The Impact of CKD on Uremic Toxins and Gut Microbiota. <i>Toxins</i> , 2021 , 13, | 4.9 | 27 |
| 43 | Heart function disturbances in chronic kidney disease - echocardiographic indices. <i>Archives of Medical Science</i> , 2014 , 10, 1109-16 | 2.9 | 26 |
| 42 | The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease. <i>International Journal of Molecular Sciences</i> , 2020 , 21, | 6.3 | 25 |
| 41 | Prevention of sudden cardiac death in patients with chronic kidney disease. <i>BMC Nephrology</i> , 2012 , 13, 162 | 2.7 | 23 |
| 40 | Treatment of non-ST-elevation myocardial infarction and ST-elevation myocardial infarction in patients with chronic kidney disease. <i>Archives of Medical Science</i> , 2013 , 9, 1019-27 | 2.9 | 20 |
| 39 | The Influence of Inflammation on Anemia in CKD Patients. <i>International Journal of Molecular Sciences</i> , 2020 , 21, | 6.3 | 19 |
| 38 | Impact of Vitamin D on the Cardiovascular System in Advanced Chronic Kidney Disease (CKD) and Dialysis Patients. <i>Nutrients</i> , 2018 , 10, | 6.7 | 19 |
| 37 | Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study. <i>Lipids in Health and Disease</i> , 2016 , 15, 22 | 4.4 | 19 |
| 36 | Sudden cardiac death in CKD patients. <i>International Urology and Nephrology</i> , 2015 , 47, 971-82 | 2.3 | 18 |
| 35 | The Use of Plant Sterols and Stanols as Lipid-Lowering Agents in Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2017 , 23, 2488-2495 | 3.3 | 18 |
| 34 | Serum NGAL, KIM-1, IL-18, L-FABP: new biomarkers in the diagnostics of acute kidney injury (AKI) following invasive cardiology procedures. <i>International Urology and Nephrology</i> , 2020 , 52, 2135-2143 | 2.3 | 14 |
| 33 | Acute coronary syndromes in patients with chronic kidney disease. <i>Current Vascular Pharmacology</i> , 2013 , 11, 758-67 | 3.3 | 14 |
| 32 | Do HDL and LDL subfractions play a role in atherosclerosis in end-stage renal disease (ESRD) patients?. <i>International Urology and Nephrology</i> , 2017 , 49, 155-164 | 2.3 | 12 |

(2021-2018)

| 31 | Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1857-1865 | 4 | 12 |
|----|---|-----|----|
| 30 | Combination drug versus monotherapy for the treatment of autosomal dominant polycystic kidney disease. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 2049-56 | 4 | 11 |
| 29 | Pharmacogenomics of Hypertension Treatment. <i>International Journal of Molecular Sciences</i> , 2020 , 21, | 6.3 | 10 |
| 28 | Evaluation of Endothelial (dys)Function, Left Ventricular Structure and Function in Patients with Chronic Kidney Disease. <i>Current Vascular Pharmacology</i> , 2016 , 14, 360-7 | 3.3 | 10 |
| 27 | Oxidative Stress in ESRD Patients on Dialysis and the Risk of Cardiovascular Diseases. <i>Antioxidants</i> , 2020 , 9, | 7.1 | 8 |
| 26 | The Problem of Atrial Fibrillation in Patients with Chronic Kidney Disease. <i>Current Vascular Pharmacology</i> , 2016 , 14, 260-5 | 3.3 | 8 |
| 25 | Cholesterol Subfraction Analysis in Patients with Acute Coronary Syndrome. <i>Current Vascular Pharmacology</i> , 2019 , 17, 365-375 | 3.3 | 8 |
| 24 | Cholesterol Disturbances and the Role of Proper Nutrition in CKD Patients. <i>Nutrients</i> , 2019 , 11, | 6.7 | 8 |
| 23 | Arterial Hypertension-Oxidative Stress and Inflammation Antioxidants, 2022, 11, | 7.1 | 7 |
| 22 | Biochemical Markers in the Prediction of Contrast-induced Acute Kidney Injury. <i>Current Medicinal Chemistry</i> , 2021 , 28, 1234-1250 | 4.3 | 7 |
| 21 | Hypertension - Current Natural Strategies to Lower Blood Pressure. <i>Current Pharmaceutical Design</i> , 2017 , 23, 2453-2461 | 3.3 | 6 |
| 20 | The Correlation between Lipid Metabolism Disorders and Prostate Cancer. <i>Current Medicinal Chemistry</i> , 2021 , 28, 2048-2061 | 4.3 | 6 |
| 19 | Acute Kidney Injury in COVID-19. International Journal of Molecular Sciences, 2021, 22, | 6.3 | 6 |
| 18 | The occurrence of atrial fibrillation in dialysis patients and its association with left atrium volume before and after dialysis. <i>International Urology and Nephrology</i> , 2017 , 49, 1071-1077 | 2.3 | 5 |
| 17 | The Role of Metabolic Factors in Renal Cancers. <i>International Journal of Molecular Sciences</i> , 2020 , 21, | 6.3 | 5 |
| 16 | Are Markers of Cardiac Dysfunction Useful in the Assessment of Cardiovascular Risk in Dialysis Patients?. <i>Current Pharmaceutical Design</i> , 2017 , 23, 3024-3033 | 3.3 | 4 |
| 15 | Lipoprotein Subfractions, Uric Acid and Cardiovascular Risk in End-Stage Renal Disease (ESRD) Patients. <i>Current Vascular Pharmacology</i> , 2017 , 15, 123-134 | 3.3 | 3 |
| 14 | Diabetes and Cardiovascular Risk in Renal Transplant Patients. <i>International Journal of Molecular Sciences</i> , 2021 , 22, | 6.3 | 3 |

| 13 | miRNA biomarkers in renal disease. International Urology and Nephrology, 2021, 1 | 2.3 | 3 |
|----|---|-----|---|
| 12 | Are Nutraceuticals Beneficial in Chronic Kidney Disease?. <i>Pharmaceutics</i> , 2021 , 13, | 6.4 | 3 |
| 11 | Emerging Anti-Atherosclerotic Therapies. International Journal of Molecular Sciences, 2021, 22, | 6.3 | 2 |
| 10 | Biomarkers of Cardiovascular Risk in Haemodialysis Patients. <i>Current Pharmaceutical Design</i> , 2018 , 23, 6086-6095 | 3.3 | 2 |
| 9 | Diabetes-induced Alterations in HDL Subfractions Distribution. <i>Current Pharmaceutical Design</i> , 2020 , 26, 3341-3348 | 3.3 | 2 |
| 8 | Metabolomic Profile in Venous Thromboembolism (VTE). <i>Metabolites</i> , 2021 , 11, | 5.6 | 2 |
| 7 | Impact of Continuous Erythropoietin Receptor Activator on Selected Biomarkers of Cardiovascular Disease and Left Ventricle Structure and Function in Chronic Kidney Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2016 , 2016, 9879615 | 6.7 | 2 |
| 6 | Molecular Interactions of Arterial Hypertension in Its Target Organs. <i>International Journal of Molecular Sciences</i> , 2021 , 22, | 6.3 | 2 |
| 5 | Oxidative Stress-Related Susceptibility to Aneurysm in Marfan's Syndrome. <i>Biomedicines</i> , 2021 , 9, | 4.8 | 2 |
| 4 | Mineralocorticoid Receptor Antagonists-Use in Chronic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2021 , 22, | 6.3 | 2 |
| 3 | Pathomechanisms of Immunological Disturbances in EThalassemia. <i>International Journal of Molecular Sciences</i> , 2021 , 22, | 6.3 | 2 |
| 2 | Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases. <i>International Journal of Molecular Sciences</i> , 2017 , 18, | 6.3 | 1 |
| 1 | Is a High HDL-Cholesterol Level Always Beneficial?, <i>Biomedicines</i> , 2021 , 9, | 4.8 | 1 |